SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. ("ZYUS"), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is proud to announce that it has launched direct sales and distribution of products to registered medical patients across Canada through its newly-launched ZYUS.ca website. ZYUS can now begin selling its first-generation cannabinoid-based formulations directly to eligible medical patients. This achievement marks a critical milestone in ZYUS’ mission to improve quality of life for patients through plant-made therapeutics – leveraging cannabinoids and their transformational potential.
A Different Approach to Patient Care
ZYUS is committed to the utmost quality, with all products undergoing rigorous testing from production to packaging and distribution, to ensure consistent and standardized formulations. Starting today, eligible medical patients can register for access to ZYUS’ products via ZYUS.ca or by contacting the ZYUS Patient Care Team at 1-833-713-CARE (2273). ZYUS’ approach to patient care emphasizes empathy, awareness and compassion, helping patients access the support and relief they need throughout their journey to improved quality of life. In the coming months, ZYUS intends to expand its product offerings to provide more options for patients and healthcare practitioners (HCPs) seeking to manage a range of symptoms.
Three Simple Steps to Registration
Eligible medical patients looking to purchase ZYUS products can register directly on ZYUS.ca through a simple and streamlined three-step process:
- Download a medical document for their HCP to complete: A healthcare practitioner is required to complete the medical document on behalf of the patient.
- Complete the patient application: The application to register can either be completed directly on ZYUS.ca or via a downloadable document.
- Confirmation of Registration: Patients will receive an email or a call that confirms their registration and introduces them to the ZYUS patient care team.
ZYUS takes a different approach to care and offers a range of resources for patients and HCPs at ZYUS.ca as well as compassionate support from the ZYUS patient care team.
“We are proud to welcome patients to ZYUS and to support them on their journey to improved quality of life by launching direct sales for medical purposes,” said ZYUS CEO Brent Zettl. “Patients are at the heart of our business, and our mission is to help all patients improve their quality of life by unlocking the extraordinary potential of plant-made therapeutics. With millions of Canadians still suffering and managing pain daily, we recognize that the mission is not over yet. ZYUS will lead the development of the next generation of life sciences to have a transformational impact on patients’ lives. We look forward to welcoming patients today, and to launching more products to address their needs in the coming months.”
Prospective patients or HCPs seeking more information on ZYUS or its products can visit ZYUS.ca or speak to a member of the ZYUS patient care team at 1-833-713-CARE (2273).
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com
Forward-Looking Information
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, expectations with respect to our business plans, research activities and product lines.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information respecting the proposed research or results therefrom, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
